Incidence and epidemiology of levofloxacin resistance in Streptococcus pneumoniae: Experience from a tertiary referral hospital in England

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 3, 2009, Pages 449-452

  Orr, David ^a   Wilkinson, Paul ^a   Moyce, Laura ^b   Martin, Siobhan ^b   George, Robert ^b   Pichon, Bruno ^b  

^a ROYAL PRESTON HOSPITAL   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

gyrA; MLST; Mutations; parC; Pneumonia

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; LEVOFLOXACIN; PROTEIN PARC;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BACTERIUM ISOLATE; CHILD; CONTROLLED STUDY; FEMALE; GENE IDENTIFICATION; GENE MUTATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTILOCUS SEQUENCE TYPING; NONHUMAN; NUCLEOTIDE SEQUENCE; PNEUMOCOCCAL INFECTION; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; TERTIARY HEALTH CARE; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIAL TYPING TECHNIQUES; BETA-LACTAM RESISTANCE; DNA FINGERPRINTING; DNA GYRASE; DNA TOPOISOMERASE IV; ENGLAND; FEMALE; GENOTYPE; HOSPITALS, TEACHING; HUMANS; INCIDENCE; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OFLOXACIN; SEQUENCE ANALYSIS, DNA; SEROTYPING; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; YOUNG ADULT;

EID: 77950334546     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp463     Document Type: Article

References (10)

1. Pelle B, Gilchrist M, Lawson W et al. Using defined daily doses to study the use of antibacterials in UK hospitals. Hospital Pharmacist 2006; 13: 133-6.
2. Pichon B, Bennett HV, Efstratiou A et al. Genetic characteristics of pneumococcal disease in elderly patients before introducing the pneumococcal conjugate vaccine. Epidemiol Infect 2009; 137: 1049-56.
3. Platt S, Pichon B, George R et al. A bioinformatics pipeline for high-throughput microbial multilocus sequence typing (MLST) analyses. Clin Microbiol Infect 2006; 12: 1144-6.
4. Pan XS, Fisher LM. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob Agents Chemother 1997; 41:471-4.
5. Andrews JM for the BSAC Working Party on Susceptibility Testing. BSAC standardized disc susceptibility testing method (version 8). J Antimicrob Chemother 2009; 64: 454-89.
6. Davidson R, Rodrigo C, James L et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 747-50.
7. Anderson K, Tan J, File T et al. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 2003; 37: 376-81.
8. Lim S, Bast D, McGeer A et al. Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg Infect Dis 2003; 9: 833-7.
9. Allen G, Kaatz G, Rybak M. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003; 47: 2606-14.
10. Rozen D, McGee L, Levin B et al. Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2007; 31: 412-6.